182 related articles for article (PubMed ID: 34062302)
1. HER2 Receptor Conversion Is a strong Survival Predictor in Patients with Breast Cancer Brain Metastases.
Michel A; Oppong MD; Rauschenbach L; Pierscianek D; Dinger TF; Schmidt T; Hense J; Pöttgen C; Kimmig R; Ahmadipour Y; Özkan N; Müller O; Junker A; Sure U; Jabbarli R; El Hindy N
World Neurosurg; 2021 Aug; 152():e332-e343. PubMed ID: 34062302
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
3. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
[TBL] [Abstract][Full Text] [Related]
4. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.
Duchnowska R; Dziadziuszko R; Trojanowski T; Mandat T; Och W; Czartoryska-Arłukowicz B; Radecka B; Olszewski W; Szubstarski F; Kozłowski W; Jarosz B; Rogowski W; Kowalczyk A; Limon J; Biernat W; Jassem J;
Breast Cancer Res; 2012 Aug; 14(4):R119. PubMed ID: 22898337
[TBL] [Abstract][Full Text] [Related]
5. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
[TBL] [Abstract][Full Text] [Related]
6. Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy.
Timmer M; Werner JM; Röhn G; Ortmann M; Blau T; Cramer C; Stavrinou P; Krischek B; Mallman P; Goldbrunner R
Anticancer Res; 2017 Sep; 37(9):4859-4865. PubMed ID: 28870906
[TBL] [Abstract][Full Text] [Related]
7. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.
Melisko ME; Moore DH; Sneed PK; De Franco J; Rugo HS
J Neurooncol; 2008 Jul; 88(3):359-65. PubMed ID: 18398574
[TBL] [Abstract][Full Text] [Related]
8. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
9. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
10. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
Sperduto PW; Kased N; Roberge D; Chao ST; Shanley R; Luo X; Sneed PK; Suh J; Weil RJ; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
J Neurooncol; 2013 May; 112(3):467-72. PubMed ID: 23462853
[TBL] [Abstract][Full Text] [Related]
11. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
Chen R; Qarmali M; Siegal GP; Wei S
Mod Pathol; 2020 Dec; 33(12):2499-2506. PubMed ID: 32620918
[TBL] [Abstract][Full Text] [Related]
12. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
Mohammad AM; Abdel HA; Abdel W; Ahmed AM; Wael T; Eiman G
Indian J Cancer; 2006; 43(4):163-8. PubMed ID: 17192687
[TBL] [Abstract][Full Text] [Related]
14. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
[TBL] [Abstract][Full Text] [Related]
15. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.
Sperduto PW; Kased N; Roberge D; Xu Z; Shanley R; Luo X; Sneed PK; Chao ST; Weil RJ; Suh J; Bhatt A; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2111-7. PubMed ID: 21497451
[TBL] [Abstract][Full Text] [Related]
16. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
Schrijver WAME; Suijkerbuijk KPM; van Gils CH; van der Wall E; Moelans CB; van Diest PJ
J Natl Cancer Inst; 2018 Jun; 110(6):568-580. PubMed ID: 29315431
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
[TBL] [Abstract][Full Text] [Related]
20. Relationship between HER2 Proto-oncogene Status and Prognostic Factors of Breast Cancer in the West of Iran.
Amirifard N; Sadeghi E; Payandeh M; Mohebbi H; Sadeghi M; Choubsaz M
Asian Pac J Cancer Prev; 2016; 17(1):295-8. PubMed ID: 26838227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]